Panbela announces positive preclinical data strongly supporting the activity of sbp-101 in ovarian cancer cell lines; development program for sbp-101's expansion into ovarian cancer expected in 1h 2022

Company to host a virtual r&d day to discuss the new ovarian cancer program in the new year company to host a virtual r&d day to discuss the new ovarian cancer program in the new year
PBLA Ratings Summary
PBLA Quant Ranking